| Symbol | ACIU |
|---|---|
| Name | AC IMMUNE SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | EPFL INNOVATION PARK,BUILDING B, LAUSANNE, 1015, Switzerland |
| Telephone | +41 216939121 |
| Fax | — |
| — | |
| Website | https://www.acimmune.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001651625 |
| Description | AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Additional info from NASDAQ: |
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Read moreDirector Twyman Roy Ervin 🟢 acquired 55.5K shares (1 derivative) of AC Immune SA (ACIU) at $2.62 Transaction Date: Jun 11, 2026 | Filing ID: 000012
Read moreDirector AGUIAR-LUCANDER RENEE 🟢 acquired 55.5K shares (1 derivative) of AC Immune SA (ACIU) at $2.62 Transaction Date: Jun 11, 2026 | Filing ID: 000011
Read moreDirector Zuegel Martin 🟢 acquired 110.9K shares (1 derivative) of AC Immune SA (ACIU) at $2.62 Transaction Date: Jun 11, 2026 | Filing ID: 000010
Read moreDirector Buetler Monika 🟢 acquired 59.4K shares (1 derivative) of AC Immune SA (ACIU) at $2.62 Transaction Date: Jun 11, 2026 | Filing ID: 000009
Read moreDirector June Carl Howard 🟢 acquired 55.5K shares (1 derivative) of AC Immune SA (ACIU) at $2.62 Transaction Date: Jun 11, 2026 | Filing ID: 000008
Read moreAC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
Read moreDirector Pfeifer Andrea 🔴 sold 10.0K shares of AC Immune SA (ACIU) at $2.79 Transaction Date: May 15, 2026 | Filing ID: 000007
Read more📋 ANDREA M.A PFEIFER (Director) plans to sell 20K shares of AC IMMUNE SA (at $2.80 each, total $56K) Filed: May 15, 2026 | ID: 004616
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07463196 | A Study Investigating the Safety, Absorption, Elimination, and the Effect on th… | Phase1 | Healthy Participants | Recruiting | 2026-01-28 | 2026-08-01 | ClinicalTrials.gov |
| NCT06891703 | [18F]ACI-15916 PET in α-synucleinopathies | Early_Phase1 | Parkinson's Disease (PD) | Recruiting | 2025-03-20 | 2026-03-01 | ClinicalTrials.gov |
| NCT06891716 | [18F]ACI-19626 PET in TDP-43 Proteinopathies | Early_Phase1 | Frontotemporal Dementia (FTD) | Recruiting | 2025-01-21 | 2026-11-01 | ClinicalTrials.gov |
| NCT06015841 | A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages o… | Phase2 | Parkinson Disease | Active_Not_Recruiting | 2023-07-24 | 2028-01-01 | ClinicalTrials.gov |
| NCT05462106 | A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down … | Phase1 | Amyloid Plaque | Recruiting | 2022-06-21 | 2029-04-01 | ClinicalTrials.gov |
| NCT04373616 | A Study of ACI-24 in Adults With Down Syndrome | Phase2 | Down Syndrome | Withdrawn | 2021-10-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT05067192 | Optimization of Morphomer-based Alpha-synuclein PET Tracers | — | Parkinson Disease | Completed | 2021-07-15 | 2021-09-01 | ClinicalTrials.gov |
| NCT06445465 | Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Depos… | Early_Phase1 | Alpha-Synucleinopathy | Completed | 2020-12-24 | 2024-11-26 | ClinicalTrials.gov |
| NCT04445831 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted… | Phase1 | Alzheimer's Disease | Completed | 2019-07-31 | 2023-09-05 | ClinicalTrials.gov |
| NCT02738450 | Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down S… | Phase1 | Down Syndrome | Completed | 2016-03-01 | 2020-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 1b) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 2) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 1a) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 1b) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A in Study Part 2 | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 2) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A in Study Part 1a | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo (Study Part 1a) | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo | Other | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |
| ACI-24 high dose | Other | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |
| ACI-24 low dose | Other | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |
| Placebo | Other | Phase PHASE2 | Down Syndrome | WITHDRAWN | NCT04373616 |
| ACI-24 | Other | Phase PHASE2 | Down Syndrome | WITHDRAWN | NCT04373616 |
| JACI-35.054 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| ACI-35.030 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| [18F]MNI-1216 | Other | Phase EARLY_PHASE1 | Alpha-Synucleinopathy | COMPLETED | NCT06445465 |
| [18F]ACI-19626 | Other | Phase EARLY_PHASE1 | Frontotemporal Dementia (FTD) | RECRUITING | NCT06891716 |
| [18F]ACI-15916 | Other | Phase EARLY_PHASE1 | Parkinson's Disease (PD) | RECRUITING | NCT06891703 |
| ACI-7104.056 at Dose C (optional) | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose B (optional) | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose A | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| Placebo | Other | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-24.060 at Dose D | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| Placebo | Other | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-19764 at dose B3 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B2 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B1 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A6 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A5 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A4 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A3 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A2 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A1 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B3 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B2 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose B1 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A6 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A5 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A4 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A3 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A2 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-19764 at dose A1 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| [18F]ACI-19626 | OTHER | Phase EARLY_PHASE1 | Frontotemporal Dementia (FTD) | RECRUITING | NCT06891716 |
| [18F]ACI-15916 | OTHER | Phase EARLY_PHASE1 | Parkinson's Disease (PD) | RECRUITING | NCT06891703 |
| [18F]MNI-1216 | DRUG | Phase EARLY_PHASE1 | Alpha-Synucleinopathy | COMPLETED | NCT06445465 |
| ACI-7104.056 at Dose C (optional) | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose B (optional) | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-7104.056 at Dose A | BIOLOGICAL | Phase PHASE2 | Parkinson Disease | ACTIVE_NOT_RECRUITING | NCT06015841 |
| ACI-24.060 at Dose D | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose C | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose B | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| ACI-24.060 at Dose A | BIOLOGICAL | Phase PHASE1 | Amyloid Plaque | RECRUITING | NCT05462106 |
| JACI-35.054 | BIOLOGICAL | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| ACI-35.030 | BIOLOGICAL | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT04445831 |
| ACI-24 | BIOLOGICAL | Phase PHASE2 | Down Syndrome | WITHDRAWN | NCT04373616 |
| Placebo | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07463196 |
| ACI-24 high dose | BIOLOGICAL | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |
| ACI-24 low dose | BIOLOGICAL | Phase PHASE1 | Down Syndrome | COMPLETED | NCT02738450 |